Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 135

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 135
---
son Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers                                                               
 of Anson Investments Master Fund LP (“AIMF”), hold voting and dispositive power over the Common Shares held by AIMF. Tony                  
 Moore is the managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin   
 Nathoo are directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of these Common Shares 
 except to the extent of their pecuniary interest therein. The principal business address of AIMF is Maples Corporate Services Limited,     
 PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.                                                                          |

| (8) | The selling stockholder is affiliated with H.C. Wainwright & Co.,                                                                          
 LLC, a registered broker dealer with a registered address of H.C. Wainwright & Co., LLC, 430 Park Ave, 3rd Floor, New York, NY 10022.      
 The selling stockholder has sole voting and dispositive power over the shares. The number of shares beneficially owned consists of shares  
 of Common Stock issuable upon exercise of Placement Agent Warrants, which were received as compensation in connection with our private     
 placement transactions in January 2025 and February 2025. The selling stockholder acquired the Placement Agent Warrants in the ordinary    
 course of business and, at the time the Placement Agent Warrants were acquired, the selling stockholder had no agreement or understanding, 
 directly or indirectly, with any person to distribute such securities.                                                                     |

79 BUSINESS Overview We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir. Mission Our mission is to address the unmet medical need associated with infectious diseases through the development and commercialization of new small molecule therapeutics, focusing